#USA #New York #Class Action #Pomerantz Law #Rocket Pharmaceuticals

Investor Alert: Class Action Lawsuit Against Rocket Pharmaceuticals

Pomerantz LLP has issued an important notice to investors of Rocket Pharmaceuticals, Inc. regarding a class action lawsuit aimed at addressing potential securities fraud or unlawful business practices within the company. The lawsuit revolves around harmful disclosures tied to Rocket's investigational products, which have raised concern among shareholders.

Background of the Lawsuit

The class action was initiated following distressing news concerning Rocket's gene therapy candidate, RP-A501. On May 27, 2025, Rocket announced a significant setback regarding a patient enrolled in the Phase 2 pivotal trial for the therapy targeting Danon disease. The announcement revealed that the patient had experienced a serious adverse event related to capillary leak syndrome, ultimately leading to the patient's unfortunate death.

This information, disclosed in a press release, triggered a sharp decline in Rocket's stock price, leading to a staggering drop of over 62%. The litigation aims to investigate whether the executives of the company engaged in deceptive practices that misled investors regarding the safety and efficacy of its therapies.

Key Dates for Investors

Investors looking to participate in the class action must act swiftly, as the deadline to request to be appointed as Lead Plaintiff is August 11, 2025. Interested parties are encouraged to reach out to Pomerantz LLP directly, providing their contact details and the scope of their investments during the class period.

How Pomerantz Law Firm Can Help

Pomerantz LLP is a highly regarded law firm specializing in corporate and securities class litigation. Not only has the firm built a reputation for advocating for the rights of shareholders, but it has also successfully recovered substantial damages on behalf of investors in previous class actions. For more than eight decades, Pomerantz has upheld the legacy founded by Abraham L. Pomerantz, often regarded as the pioneer in class action lawsuits.

Next Steps for Affected Investors

Investors adversely affected by the recent happenings with Rocket Pharmaceuticals are urged to remain informed and proactive. Those with losses related to their shares should consider consulting with Pomerantz LLP to learn about their options. The firm provides resources and legal expertise to guide investors through the complexities of securities litigation.

In short, if you believe you have been impacted by Rocket Pharmaceuticals' actions, now is the time to take action. Contact Danielle Peyton at Pomerantz LLP, and ensure your voice is heard in this critical legal matter.

Contact Information

For further inquiries and to join the class action, investors may reach out to:

• - Danielle Peyton
• - Phone: 646-581-9980 or 888.4-POMLAW (Ext. 7980)
• - Email: email protected]
• - Website for more details: [www.pomerantzlaw.com

Keep in mind that time is of the essence when dealing with class actions. Evaluating your options and participating in legal proceedings can be pivotal in seeking justice and recovering losses incurred due to securities violations.